600079.SH
ST人福
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 17.85
−0.22%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 23.9B | 24.0B | 25.4B | 24.5B | 22.3B |
| Cost of Revenue | 12.3B | 12.4B | 14.1B | 13.3B | 12.6B |
| Gross Profit | 11.6B | 11.6B | 11.3B | 11.2B | 9.7B |
| Operating Expenses | |||||
| R&D Expense | 1.5B | 1.5B | 1.5B | 1.5B | 966.9M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 1.7B | 1.7B | 1.9B | 1.8B | 1.6B |
| Selling & Marketing Expense | 4.5B | 4.5B | 4.6B | 4.4B | 4.3B |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 8.2B | 8.2B | 8.6B | 8.1B | 7.2B |
| Cost and Expenses | 20.5B | 20.6B | 22.7B | 21.4B | 19.9B |
| Operating Income (EBIT) | 3.3B | 3.2B | 2.5B | 3.4B | 3.5B |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 3.2B | 3.1B | 2.4B | 3.4B | 3.4B |
| Income Tax Expense | 605.3M | 564.0M | 644.5M | 568.6M | 354.8M |
| Bottom Line | |||||
| Net Income | 1.9B | 1.9B | 1.3B | 2.1B | 2.5B |
| Earnings from Cont. Ops | 2.6B | 2.5B | 1.8B | 2.8B | 3.1B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 1.9B | 1.9B | 1.3B | 2.1B | 2.5B |
| Per Share | |||||
| Basic EPS | CN¥1.17 | CN¥1.14 | CN¥0.82 | CN¥1.32 | CN¥1.54 |
| Diluted EPS | CN¥1.17 | CN¥1.14 | CN¥0.82 | CN¥1.31 | CN¥1.54 |
| Revenue Per Share | CN¥14.64 | CN¥14.72 | CN¥15.69 | CN¥15.17 | CN¥13.85 |
| Shares | |||||
| Basic Shares Outstanding | 1.6B | 1.6B | 1.6B | 1.6B | 1.6B |
| Diluted Shares Outstanding | 1.6B | 1.6B | 1.6B | 1.6B | 1.6B |
| Profitability Metrics | |||||
| EBITDA | — | 4.2B | 3.5B | 4.2B | 4.3B |
| D&A | — | 1.0B | 1.0B | 802.2M | 738.3M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026